echemi logo
Product
  • Product
  • Supplier
  • Inquiry
    Home > Biochemistry News > Biotechnology News > Innovative T-cell cancer immunotherapy recognized by FDA breakthrough therapy

    Innovative T-cell cancer immunotherapy recognized by FDA breakthrough therapy

    • Last Update: 2020-06-09
    • Source: Internet
    • Author: User
    Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com
    Cervical cancer is most common among women aged 35-44Cervical cancer mortality rates have decreased significantly as a result of the use of early detection methods such as Pap smearsHowever, the mortality rate from cervical cancer has not improved further over the past 15 yearsIovance TIL therapy is an auto-relayed T-cell cancer immunotherapyIt takes TIL from the patient and then uses IL-2 cytokine in vitro to stimulate TIL amplificationIn vitro stimulation not only increases the number of TIL, but also activates TIL's anti-tumor abilityThese TIs are then injected back into the patient, where they can kill tumor cells more effectivelyLN-145 Therapy Mechanism (Photo: Iovance,com.au)The FDA's award of breakthrough therapy was determined to be based on LN-145's performance in early clinical trials for the treatment of patients with advanced cervical cancerPatients treated with LN-145 received an average of 2.6 pre-treatmentsLN-145 achieved an objective remission rate (ORR) and 89% of disease control rates in clinical trialsAfter 1 treatment, of the 27 patients who were able to be assessed, 1 achieved full remission, 9 reached partial remission and 2 reached unconfirmed partial remissionIovance will present the latest results of the trial at this year's annual meeting of the American Society of Clinical Oncology (ASCO)"We are very pleased that the FDA has awarded LN-145 a breakthrough therapy for the treatment of advanced cervical cancerCervical cancer patients who continue to develop after chemotherapy have limited treatment options, and we hope to bring LN-145 to patients as soon as possible," said DrMaria Fardis, President and CEO of IovanceReferences: Retrieved May 22, 2019, from https://apnews.com/Globe%20Newswire/06fe6a68fad69eb1232dcb909f5158c5 Retrieved May 22, 2019, from https://
    This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

    Contact Us

    The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

    Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.